Login / Signup

Mouse pulmonary interstitial macrophages mediate the pro-tumorigenic effects of IL-9.

Yongyao FuAbigail PajulasJocelyn WangBaohua ZhouAnthony CannonCherry Cheuk Lam CheungJilu ZhangHuaxin ZhouAmanda Jo FisherDavid T OmsteadSabrina KhanLei HanJean-Christophe RenauldSophie PaczesnyHongyu GaoYunlong LiuLei YangRobert M TighePaula Licona-LimónRichard A FlavellShogo TakatsukaDaisuke KitamuraJie SunBasar BilgicerCatherine R SearsKai YangMark H Kaplan
Published in: Nature communications (2022)
Although IL-9 has potent anti-tumor activity in adoptive cell transfer therapy, some models suggest that it can promote tumor growth. Here, we show that IL-9 signaling is associated with poor outcomes in patients with various forms of lung cancer, and is required for lung tumor growth in multiple mouse models. CD4 + T cell-derived IL-9 promotes the expansion of both CD11c + and CD11c - interstitial macrophage populations in lung tumor models. Mechanistically, the IL-9/macrophage axis requires arginase 1 (Arg1) to mediate tumor growth. Indeed, adoptive transfer of Arg1 + but not Arg1 - lung macrophages to Il9r -/- mice promotes tumor growth. Moreover, targeting IL-9 signaling using macrophage-specific nanoparticles restricts lung tumor growth in mice. Lastly, elevated expression of IL-9R and Arg1 in tumor lesions is associated with poor prognosis in lung cancer patients. Thus, our study suggests the IL-9/macrophage/Arg1 axis is a potential therapeutic target for lung cancer therapy.
Keyphrases
  • poor prognosis
  • cancer therapy
  • adipose tissue
  • long non coding rna
  • mouse model
  • risk assessment
  • nitric oxide
  • drug delivery
  • single cell
  • weight loss
  • nk cells
  • genetic diversity
  • wild type
  • oxide nanoparticles